Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11357-021-00323-3 http://scihub22266oqcxt.onion/10.1007/s11357-021-00323-3 33569701!7875765!33569701     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Geroscience 2021 ; 43 (1): 31-51 Nephropedia Template TP {{tp|p=33569701|t=2021. The impact of immuno-aging on SARS-CoV-2 vaccine development |pdf=|usr=}}{{33569701}} gab.com Text The impact of immuno-aging on SARS-CoV-2 vaccine development JO: Geroscience http://www.kidney.de/pget.php?&tw=1&pmid=33569701 #FOAvip The SARS-CoV-2 pandemic has almost 56 million confirmed cases resulting in over 1.3 million deaths as of November 2020. This infection has proved more deadly to older adults (those >65 years of age) and those with immunocompromising conditions. The worldwide population aged 65 years and older is increasing, and the total number of aged individuals will outnumber those younger than 65 years by the year 2050. Aging is associated with a decline in immune function and chronic activation of inflammation that contributes to enhanced viral susceptibility and reduced responses to vaccination. Here we briefly review the pathogenicity of the virus, epidemiology and clinical response, and the underlying mechanisms of human aging in improving vaccination. We review current methods to improve vaccination in the older adults using novel vaccine platforms and adjuvant systems. We conclude by summarizing the existing clinical trials for a SARS-CoV-2 vaccine and discussing how to address the unique challenges for vaccine development presented with an aging immune system. Twit Text FOAVip The impact of immuno-aging on SARS-CoV-2 vaccine development ????Geroscience http://www.kidney.de/pget.php?&tw=1&pmid=33569701 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33569701 #FOAvip English Wikipedia <ref>{{Cite pmid|33569701}}</ref> The impact of immuno-aging on SARS-CoV-2 vaccine development #MMPMID33569701 Connors J; Bell MR; Marcy J; Kutzler M; Haddad EK Geroscience 2021[Feb]; 43 (1): 31-51 PMID33569701show ga The SARS-CoV-2 pandemic has almost 56 million confirmed cases resulting in over 1.3 million deaths as of November 2020. This infection has proved more deadly to older adults (those >65 years of age) and those with immunocompromising conditions. The worldwide population aged 65 years and older is increasing, and the total number of aged individuals will outnumber those younger than 65 years by the year 2050. Aging is associated with a decline in immune function and chronic activation of inflammation that contributes to enhanced viral susceptibility and reduced responses to vaccination. Here we briefly review the pathogenicity of the virus, epidemiology and clinical response, and the underlying mechanisms of human aging in improving vaccination. We review current methods to improve vaccination in the older adults using novel vaccine platforms and adjuvant systems. We conclude by summarizing the existing clinical trials for a SARS-CoV-2 vaccine and discussing how to address the unique challenges for vaccine development presented with an aging immune system. |*COVID-19[MESH] |*Vaccines[MESH] |Aged[MESH] |Aging[MESH] |COVID-19 Vaccines[MESH] |Humans[MESH]The impact of immuno-aging on SARS-CoV-2 vaccine development (epmc).pdf DeepDyve Pubget Overpricing